When citing this article, please use: Jesudian, A.B. and Jacobson, I.M. Telaprevir for Chronic Hepatitis C Virus Infection. Clinics in Liver Disease 2013; 17:47–62
Optimal treatment with telaprevir for chronic HCV infection
Article first published online: 3 JAN 2013
Copyright © 2013 Elsevier Inc.
Special Issue: Proceedings of the 6th Paris Hepatitis Conference, International Conference on the Management of Patients with Viral Hepatitis
Volume 33, Issue Supplement s1, pages 3–13, February 2013
How to Cite
Jesudian, A. B. and Jacobson, I. M. (2013), Optimal treatment with telaprevir for chronic HCV infection. Liver International, 33: 3–13. doi: 10.1111/liv.12079
- Issue published online: 3 JAN 2013
- Article first published online: 3 JAN 2013
- direct-acting antivirals;
- hepatitis C virus;
Telaprevir is a recently approved direct-acting antiviral against hepatitis C virus (HCV) that works through inhibition of the NS3/4A serine protease inhibitor.Phase 2b and 3 studies have shown marked increase in sustained virological response rates in both treatment- naïve and treatment-experienced patients with HCV genotype 1 treated with a telaprevir-containing regimen compared with pegylated interferon (PEG-IFN) and ribavirin alone. The most commonly observed side effects of telaprevir therapy are anaemia to a greater degree than that observed with PEG-IFN/ribavirin alone; eczematous rash, which can be severe in a minority of patients; and anorectal discomfort.